DARPP-32 is a dual-function protein kinase/phosphatase inhibitor that is involved in striatal signaling. The phosphorylation of DARPP-32 at threonine 34 is essential for mediating the effects of both psychostimulant and antipsychotic drugs; however, these drugs are known to have opposing behavioral and clinical effects. We hypothesized that these drugs exert differential effects on striatonigral and striatopallidal neurons, which comprise distinct output pathways of the basal ganglia. To directly test this idea, we developed bacterial artificial chromosome transgenic mice that allowed the analysis of DARPP-32 phosphorylation selectively in striatonigral and striatopallidal neurons. Using this new methodology, we found that cocaine, a psychostimulant, and haloperidol, a sedation-producing antipsychotic, exert differential effects on DARPP-32 phosphorylation in the two neuronal populations that can explain their opposing behavioral effects. Furthermore, we found that a variety of drugs that target the striatum have cell type-specific effects that previous methods were not able to discern.
DARPP-32 is a dual-function protein kinase/phosphatase inhibitor that is involved in striatal signaling. The phosphorylation of DARPP-32 at threonine 34 is essential for mediating the effects of both psychostimulant and antipsychotic drugs; however, these drugs are known to have opposing behavioral and clinical effects. We hypothesized that these drugs exert differential effects on striatonigral and striatopallidal neurons, which comprise distinct output pathways of the basal ganglia. To directly test this idea, we developed bacterial artificial chromosome transgenic mice that allowed the analysis of DARPP-32 phosphorylation selectively in striatonigral and striatopallidal neurons. Using this new methodology, we found that cocaine, a psychostimulant, and haloperidol, a sedation-producing antipsychotic, exert differential effects on DARPP-32 phosphorylation in the two neuronal populations that can explain their opposing behavioral effects. Furthermore, we found that a variety of drugs that target the striatum have cell type-specific effects that previous methods were not able to discern.
Since its discovery 25 years ago, many studies have established that DARPP-32 is a key regulator of signaling in striatal neurons 1 . DARPP-32 function depends on its relative state of phosphorylation at two main regulatory sites, threonine 34 (T34) and threonine T75 (T75). When DARPP-32 is phosphorylated at T34 by protein kinase A (PKA), it becomes a potent inhibitor of protein phosphatase 1 (PP-1), which in turn regulates the phosphorylation state of several classes of effector proteins, including transcription factors, ionotropic receptors and ion channels 2 . PKA also phosphorylates and activates protein phosphatase 2A (PP-2A), which dephosphorylates DARPP-32 at T75 (refs. 3,4) . When phosphorylated at T75 by cdk5, DARPP-32 becomes an inhibitor of PKA signaling, thereby relieving inhibition of PP-1 (ref. 5) .
Biochemical studies have shown that a variety of therapeutic agents and drugs of abuse regulate DARPP-32 phosphorylation at T34 and T75 (ref. 6 ). Acute administration of psychostimulants such as cocaine enhances dopamine signaling and has been shown to increase T34 phosphorylation 7, 8 . Antipsychotics such as haloperidol block dopamine signaling via antagonism of dopamine type 2 receptors (D2Rs), but also increase T34 phosphorylation to a similar degree 9 . Despite this similar biochemical effect, psychostimulants and antipsychotics have opposing behavioral and clinical outcomes.
Regarding this paradox, we hypothesized that these drugs selectively target different subpopulations of striatal cells, namely striatonigral and striatopallidal neurons. These neurons are morphologically similar and are expressed homogeneously throughout the striatum; however, they are known to differ in their efferent projections and their expression of different subtypes of neurotransmitter receptors. Striatonigral neurons project via the direct pathway to the output nuclei of the basal ganglia and preferentially express dopamine type 1 receptors (D1Rs) 10 . D1Rs are coupled to G s/olf proteins, which, on activation, stimulate adenylyl cyclase, promote the formation of cAMP and activate PKA 11, 12 . On the basis of the classical model of the basal ganglia, activation of the direct pathway is expected to facilitate locomotor behavior 13 . In contrast, striatopallidal neurons project via the indirect pathway and exert an opposing influence on the output of the basal ganglia resulting in inhibition of locomotion 13 . Striatopallidal neurons express high levels of D2Rs and adenosine A 2A receptors 10, 14 . D2Rs are coupled to G i proteins, which inhibit the formation of cAMP, thereby decreasing PKA activity 12 .
Direct evidence for the hypothesis that cocaine and haloperidol differentially target these two neuronal populations has been lacking because of the inability to distinguish phosphorylation responses in these neurons. Traditional biochemical experiments have the limitation that they examine a mixed population of cells and the results of these studies represent an average of signaling events in the striatum. To overcome this, we developed bacterial artificial chromosome (BAC) transgenic mice that express differentially tagged DARPP-32 protein selectively in D1R-enriched striatonigral and D2R-enriched striatopallidal neurons. Using two different epitope tags and a selective immunoprecipitation protocol, we purified phosphorylated DARPP-32 protein from D1R-or D2R-expressing neurons from mouse striatal tissue. This new methodology allowed a quantitative side-byside comparison of phosphorylation events occurring selectively in two distinct neuronal populations in vivo.
We applied this technique to analyze phosphorylation responses to several classes of drugs that target the striatum, namely dopamine receptor agonists, psychostimulants and antipsychotics. We found that, although cocaine and haloperidol both increased DARPP-32 T34 phosphorylation, cocaine increased T34 phosphorylation only in striatonigral neurons, whereas haloperidol acted selectively on striatopallidal neurons. In addition, we observed distinct cell type-specific patterns of phosphorylation for different subclasses of psychostimulant and antipsychotic drugs. Furthermore, we found that dopamine receptor agonists exerted different effects in vivo than in acute striatal slices, revealing the complexity of dopamine signaling in the brain.
RESULTS

Targeting striatonigral and striatopallidal neurons
To study DARPP-32 phosphorylation selectively in striatonigral and striatopallidal neurons, we generated BAC transgenic mice that express C-terminal Flag-tagged DARPP-32 and Venus fluorescent protein under the control of the Drd1a (D1R) promoter and mice that express C-terminal Myc-tagged DARPP-32 and enhanced cyan fluorescent protein (ECFP) under the control of the Drd2 (D2R) promoter (Fig. 1a) . The internal ribosome entry site (IRES) in these constructs allowed separate translation of tagged DARPP-32 and fluorescent marker proteins from the same mRNA transcript.
To confirm the expression of these constructs in the correct brain areas, we carried out in situ hybridization using a probe against green fluorescent protein (GFP) that recognized both Venus and ECFP mRNA (Fig. 1b) . There was strong striatal expression seen in both D1R-DARPP-32/Flag and D2R-DARPP-32/Myc mice. The D1R-DARPP-32/Flag mice showed additional expression in the olfactory tubercle and deep layers of the cortex, whereas the D2R-DARPP-32/ Myc mice showed expression in midbrain dopaminergic nuclei. The expression patterns of our constructs reflected the known patterns of D1R and D2R expression in mouse brain, confirming accurate expression of the transgenes.
At the cellular level, we found that only a subset of striatal cells expressed GFP mRNA in the D1R-DARPP-32/Flag (36.7%, 188 out of 512 cells) and D2R-DARPP-32/Myc (41.4%, 147 out of 355 cells) mice (Fig. 1b) . To confirm that these labeled cells were indeed striatonigral or striatopallidal neurons, we took advantage of the fact that these cell types have different projection patterns. Striatonigral neurons send distal projections to the substantia nigra pars reticulata (SNpr), whereas striatopallidal neurons project more proximally to the globus pallidus. We injected FluoroGold retrograde tracer distally into the SNpr, which was selectively taken up by axon terminals of striatonigral neurons and sent via retrograde transport to cell bodies in the striatum. Double immunofluorescence in striatal sections revealed a nearly 100% colocalization of FluoroGold and GFP in the D1R-DARPP-32/ Flag mice (Fig. 1c) and no colocalization of FluoroGold and Myc in D2R-DARPP-32/Myc mice (Fig. 1d) . These results confirmed that the D1R construct was expressed selectively in striatonigral neurons, whereas the D2R construct was excluded from these cells. As medium spiny neurons are known to project either to the SNpr or the globus pallidus, we concluded that the D2R-DARPP-32/Myc construct was expressed in striatopallidal neurons. After confirming selective targeting of the D1R and D2R constructs, the D1R-DARPP-32/Flag and D2R-DARPP-32/Myc mice were crossed to generate double transgenic mice. Staining striatal sections from D1R/D2R-DARPP-32 mice with Flag and Myc antibodies confirmed that expression of the tagged constructs was indeed restricted to different striatal cell populations (Fig. 1e) .
Cell type-specific DARPP-32 immunoprecipitations Double-transgenic D1R/D2R-DARPP-32 mice were used for all biochemical experiments, as they allow direct comparison of DARPP-32 phosphorylation in D1R-and D2R-expressing neurons in response to drug treatments in the same mouse (Fig. 2a) . The success of this method relied on accurate expression of tagged DARPP-32 protein, as well as high specificity of the Flag and Myc immunoprecipitations.
Western blotting of striatal homogenates revealed Flag-and Myc-positive bands at 32-34 kD in the D1R-DARPP-32/Flag and D2R-DARPP-32/Myc mice, respectively (Fig. 2b) . However, we found no detectable change in total DARPP-32, phospho-T34, or phospho-T75 protein levels in the transgenic mice (Fig. 2b,c) . Subsequent analysis comparing levels of tagged DARPP-32 with endogenous DARPP-32 revealed that the Flag-tagged DARPP-32 represented approximately 3% of endogenous DARPP-32, whereas the Myc-tagged DARPP-32 represented 1% of endogenous DARPP-32 ( Supplementary  Fig. 1 online) . DARPP-32 is known to be expressed at very high levels in the striatum and the difference in expression between endogenous and tagged DARPP-32 was the result of differences in strength between the DARPP-32, D1R and D2R promoters that we used to express the constructs. Tagging a small percentage of the DARPP-32 in these neurons was advantageous, as we could study cell type-specific changes in phosphorylation without perturbing the endogenous system. Indeed, we did not observe any biochemical or behavioral phenotype resulting from expression of the constructs. The fact that basal T34 and T75 phosphorylation levels were unaltered further indicates that there were Optical density (a.u.)
Total DARPP-32~~~~~~~~~~~~~P We developed an immunoprecipitation protocol using antibodies against the Flag and Myc tags that allowed selective purification of DARPP-32 from D1R-and D2R-expressing striatal neurons (Fig. 2d) . In double-transgenic mice, we confirmed that there was no contaminating Flag-tagged protein present in the Myc immunoprecipitation sample and that there was no Myc contamination in the Flag immunoprecipitation sample (Fig. 2e) . We observed a small size shift in the DARPP-32 bands from the immunoprecipitation eluates as a result of the presence of the Flag and Myc tags (Fig. 2e,f and Supplementary Fig. 1 ). Notably, we were able to detect basal levels of T34 and T75 phosphorylation in both the Flag and Myc immunoprecipitation samples showing that the tagged DARPP-32 could be phosphorylated in vivo (Fig. 2f) .
Effects of D1R and D2R agonists in striatal slices
To establish the validity of the methodology, we analyzed the effects of selective D1R and D2R agonists on DARPP-32 phosphorylation in striatonigral and striatopallidal neurons. Drugs were first tested in acutely prepared striatal slices, as the effects of D1R and D2R agonists on DARPP-32 phosphorylation have been well established in this system 3, 15 . Stimulation of G s/olf -coupled D1Rs activates the cAMP/PKA/PP-2A cascade, which increases phosphorylation of T34 and decreases phosphorylation of T75 (refs. 3,4,15) . Our results in total striatal homogenates were consistent with previous studies, as the D1R agonist SKF 81297 caused a significant increase in the amount of T34 phosphorylation (441.3% ± 64.6% of control, P o 0.01) and a trend toward a decrease in the amount of T75 phosphorylation (87.4% ± 8.3% of control; Fig. 3a,b) .
We examined phosphorylation responses in D1R and D2R neurons and found that, in D1R neurons, SKF 81297 induced a robust 12-fold increase (1,220% ± 90.3% of control, P o 0.001) in T34 phosphorylation and a significant decrease in T75 phosphorylation (70.3% ± 2% of control, P o 0.001) (Fig. 3a,b ). There were no changes in phosphorylation at either site in D2R neurons (Fig. 3a,b) .
Application of the D2R agonist quinpirole also produced effects on DARPP-32 phosphorylation that were largely cell-type specific (Fig. 3c,d) . Activation of G i -coupled D2Rs inhibits the cAMP/PKA/ PP-2A signaling cascade, resulting in a decrease in T34 phosphorylation and an increase in T75 phosphorylation in total striatal homogenates 3 . Using D1R/D2R-DARPP-32 mice, we replicated these results and found that these effects were specific to D2R neurons (T34 decreased to 38.4% ± 5% of control, P o 0.01; T75 increased to 151.7% ± 14.9% of control, P o 0.01; Fig. 3c,d) . In D1R neurons, there was no change in T34 phosphorylation; however, quinpirole induced a small increase in T75 phosphorylation (122.2% ± 6% of control, P o 0.05; Fig. 3c,d ). This effect can be explained by the stimulation of D2 autoreceptors in the slice, which would decrease dopamine release 16 , thereby indirectly affecting DARPP-32 phosphorylation in D1R neurons.
Effects of D1R and D2R agonists in vivo
Similar to striatal slices, injection of the D1R agonist SKF 81297 in vivo resulted in a large increase in T34 phosphorylation that occurred selectively in D1R neurons (219% ± 19.3% of control, P o 0.001; Fig. 4a,b) . In contrast with slices, there were moderate, but significant, increases in both T34 and T75 phosphorylation seen in D2R neurons in vivo (144% ± 10.7% of control, P o 0.01 for T34; 148% ± 13.4% of control, P o 0.01 for T75; Fig. 4a,b) . Because these effects were observed in vivo, but not in striatal slices, it is probable that they were the result of stimulation of extrastriatal D1Rs that could indirectly influence signaling in the striatum.
Injection of the D2R agonist quinpirole in vivo also resulted in changes in DARPP-32 phosphorylation in both cell types (Fig. 4c,d ). As seen with slices, quinpirole significantly decreased T34 phosphorylation (67.9% ± 4.9% of control, P o 0.001 in total homogenates; 62.4% ± 5.6% of control, P o 0.01 in D2R neurons) and increased T75 phosphorylation (112.2% ± 4.2% of control, P o 0.05 in total homogenates; 123.9% ± 8.2% of control, P o 0.05 in D2R neurons) in total striatal homogenates and D2R neurons (Fig. 4c,d) . Notably, quinpirole also caused a significant decrease in T34 phosphorylation (79.4% ± 7.7% of control, P o 0.05) and an increase in T75 phosphorylation (137.3% ± 5.4% of control, P o 0.001) in D1R neurons (Fig. 4c,d ). This D2R agonist effect on D1R neurons in vivo can be explained by the presence of D2 autoreceptors on dopaminergic nerve terminals, which negatively regulate the release of dopamine 16, 17 .
Decreased dopamine binding at D1Rs would deactivate the cAMP/PKA/PP-2A cascade, resulting in decreased T34 phosphorylation and increased T75 phosphorylation, as we observed here.
Differential effects of cocaine and haloperidol in vivo
To address the paradox of how psychostimulants and antipsychotics can produce similar effects on T34 phosphorylation in total striatum, we acutely injected D1R/D2R-DARPP-32 mice with cocaine or haloperidol. Cocaine blocks the dopamine transporter, increasing the availability of dopamine at the synapse. Increased dopamine is expected to activate both G s/olf -coupled D1Rs and G i -coupled D2Rs. It has been shown previously that acute cocaine increases T34 phosphorylation and decreases T75 phosphorylation in total striatum 3 . We reproduced these findings; however, cell type-specific analysis revealed differential and opposing effects in D1R and D2R neurons (Fig. 5a) . Specifically, we observed a robust increase in T34 phosphorylation in D1R neurons (192% ± 10.5% of control, P o 0.001), but a significant decrease in T34 phosphorylation in D2R neurons (72.5% ± 3.3% of control, P o 0.01; Fig. 5a ). Conversely, T75 phosphorylation was decreased in D1R neurons (65% ± 4.4% of control, P o 0.001) and increased in D2R neurons (123.4% ± 9.3% of control, P o 0.05) (Fig. 5a ).
Haloperidol is a typical antipsychotic that is known to be a strong antagonist of D2Rs 18 . Injection of haloperidol resulted in a markedly different pattern of DARPP-32 phosphorylation compared with cocaine (Fig. 5b) . Although haloperidol induced an increase in T34 phosphorylation in the total striatal sample that was similar to that found with cocaine (153.2% ± 5.2% of control, P o 0.001), this increase was highly specific to D2R neurons (207.8% ± 22.9% of control, P o 0.001), as there was no change in T34 phosphorylation in D1R neurons (Fig. 5b) . In addition, there was no change in T75 phosphorylation in either cell type. These results directly show that, although cocaine and haloperidol both stimulated DARPP-32 T34 phosphorylation, this effect was restricted to different cell populations.
Cell type-specific effects of caffeine and clozapine Cocaine and haloperidol act primarily on the dopaminergic system. Caffeine is a psychostimulant drug that has been shown to affect adenosine signaling via antagonism of A 2A receptors 19 . A 2A receptors are highly expressed in the striatum and selectively localized to striatopallidal neurons, where they positively regulate the cAMP/PKA/PP-2A cascade, thereby opposing D2R signaling in these cells 20 . Consistent with previous studies 21 , we found that caffeine increased T75 phosphorylation in total striatal homogenates of D1R/D2R-DARPP-32 mice (130.1% ± 8% of control, P o 0.01; Fig. 5c ). The effect of caffeine on T75 phosphorylation was found to be highly specific for D2R neurons (203.5% ± 21.3% of control, P o 0.001), as there was no effect on either phosphorylation site in D1R neurons (Fig. 5c) .
Clozapine is an example of an atypical antipsychotic drug that shows less activity at D2Rs and greater binding of other neuromodulatory receptors, such as serotonin receptors 18 . Despite differences in their receptor profiles, haloperidol and clozapine both increased T34 phosphorylation in total striatal homogenates (153.2% ± 5.2% of control, P o 0.001 for haloperidol; 140.7% ± 7.7% of control, P o 0.001 for clozapine, Fig. 5b and d) . As with haloperidol, the clozapine-induced increase in T34 phosphorylation was specific for D2R neurons (158.8% ± 16.4% of control, P o 0.001; Fig. 5d) . Notably, there were also moderate, but significant, increases in T75 phosphorylation in both D1R and D2R neurons with acute clozapine treatment that were not seen with haloperidol (140% ± 3.5% of control, P o 0.001 in D1R neurons; 130.2% ± 5.2% of control, P o 0.001 in D2R neurons, Fig. 5d ), probably reflecting the broader spectrum of receptors targeted directly by clozapine 18 .
DISCUSSION
The study of biochemical processes in the striatum has long been hindered by the difficulty of selectively studying signaling responses in striatonigral and striatopallidal neurons. To overcome this obstacle, we have developed a methodology that allows cell type-specific analysis of DARPP-32 phosphorylation in these two neuronal populations. Using this technique, we have resolved the paradox that psychostimulants and antipsychotics cause the same biochemical change in the striatum, but have opposing behavioral and clinical effects. We found that the psychostimulant cocaine increases DARPP-32 T34 phosphorylation selectively in striatonigral neurons, whereas the antipsychotic haloperidol increases T34 phosphorylation only in striatopallidal neurons. As these two populations are coupled to opposing output pathways, the differential regulation of these neurons can explain the drugs' opposing behavioral effects. Furthermore, we found that other types of psychostimulant and antipsychotic drugs also resulted in differential patterns of DARPP-32 phosphorylation in striatonigral and striatopallidal neurons, which could not be found with conventional techniques. In addition, we found that, although D1R and D2R agonists selectively target striatonigral or striatopallidal neurons in striatal slices, administration of either of these drugs in vivo affected DARPP-32 phosphorylation in both cell populations.
The importance of studying cell type-specific responses in the striatum is exemplified by our results with cocaine, which provide experimental support for the classical model of the basal ganglia. This model states that the striatonigral and striatopallidal pathways exert opposing influence on the basal ganglia's control of locomotor function 13 . A hallmark behavioral response to cocaine is a robust induction of locomotor activity 22 . It was previously shown that acute cocaine administration caused an increase in DARPP-32 T34 phosphorylation and a decrease in T75 phosphorylation, a pattern that is associated with an increase in excitability in striatal neurons 3, 23 . If this effect occurred in all striatal cells, then both pathways would be activated, effectively canceling out their behavioral effects. We observed that the cocaine-induced increase in T34 and decrease in T75 phosphorylation occurred selectively in D1R striatonigral neurons, whereas an opposite phosphorylation pattern was seen in D2R striatopallidal neurons. This differential regulation of signaling in striatonigral and striatopallidal neurons shows how cocaine, a dopamine potentiator, can modulate signaling in both pathways to result in a cooperative effect on the basal ganglia's control of locomotor behavior.
In contrast with cocaine, the typical antipsychotic haloperidol can cause behavioral sedation and catalepsy 18 . Despite their opposing behavioral effects, cocaine and haloperidol have both been shown to increase T34 phosphorylation in the striatum 3, 24 . Here we found that this increase was restricted to D1R neurons with cocaine and to D2R neurons with haloperidol. Haloperidol is expected to act on D2R-expressing striatopallidal neurons, as it has been shown to have high antagonist activity at D2 receptors 18 . Striatopallidal neurons also express A 2A receptors, which counteract D2R signaling by increasing cAMP and PKA activity 20 . Haloperidol blocks the inhibitory effect of D2R activation, shifting the balance toward positive regulation of cAMP by A 2A receptors 25 . This could account for the observed increase in T34 phosphorylation in D2R neurons.
The psychostimulant caffeine, known to be an antagonist of A 2A receptors 19 , also selectively targeted D2R striatopallidal neurons. In contrast with haloperidol, which increased T34 phosphorylation, caffeine increased T75 phosphorylation in D2R neurons. Because T34 and T75 oppositely regulate the function of DARPP-32, namely inhibition of PP-1 or PKA, respectively 2 , the differential regulation of these sites by haloperidol and caffeine suggests a biochemical mechanism for the drugs' opposing behavioral effects.
Clozapine is an example of an atypical antipsychotic drug that has low D2R activity, but has affinity for several classes of serotonergic, adrenergic, muscarinic and histaminergic receptors 18 . Although haloperidol and clozapine both increased T34 phosphorylation selectively in D2R neurons, the increase was larger with haloperidol than with clozapine. Clozapine also had additional effects on T75 phosphorylation that were present in both D1R and D2R neurons, possibly as a result of effects on serotonin receptors which are expressed in both cell types. The regulation of T34 phosphorylation in D2R neurons may represent a common mechanism of action of antipsychotics. Indeed, it has been suggested that many classes of antipsychotic drugs, regardless of their primary receptor targets, can affect D2R signaling to some degree 18 . The very high level of T34 activation in D2R neurons in response to haloperidol may, in some cases, exceed the beneficial level and reach levels associated with unwanted locomotor side effects. Consistent with this idea, clinical studies have shown that in vivo D2R occupancy by antipsychotics exceeding 80% is often associated with extrapyramidal side effects 26 . The more limited increase in T34 phosphorylation, balanced by increases in T75, seen with clozapine probably reflects this drug's ability to target several different pathways.
In addition to the study of psychostimulants and antipsychotics, we examined the effects of selective D1R and D2R agonists in vivo and in striatal slices. In acute striatal slices, where afferent and efferent connections are removed, our results followed predictions that D1R agonists would act selectively on striatonigral neurons, whereas D2R agonists would target striatopallidal neurons. In vivo, however, these agonists affected DARPP-32 phosphorylation in both cell types. This can be explained by the presence of extrastriatal D1Rs and D2Rs, which would be targeted by an in vivo injection. The effect of these receptors is readily seen in the results that we obtained using the D2R agonist quinpirole. In addition to stimulation of postsynaptic D2Rs, quinpirole activates presynaptic D2 autoreceptors on dopaminergic terminals, which inhibit the release of dopamine 16, 17 . Decreased dopamine activation of D1Rs would decrease the cAMP/PKA/PP-2A signaling cascade. Decreased PKA activity would decrease T34 phosphorylation and decreased PP-2A activity would increase T75 phosphorylation in D1R neurons, as we observed here. Although dopaminergic terminals are severed in striatal slices, decreasing overall dopaminergic tone, it is probable that stimulation of some presynaptic receptors by quinpirole further reduces dopamine release, resulting in the small effect on T75 phosphorylation that we observed in D1R neurons in striatal slices. In D2R neurons, direct activation of postsynaptic D2Rs by quinpirole overrides any change in dopamine levels induced presynaptically.
In addition to the striatum, D1Rs are expressed in the cortex and limbic regions that send glutamatergic projections to the striatum 27, 28 . Activation of these D1Rs could affect striatal glutamate release, which would result in complex changes in both T34 and T75 phosphorylation in both striatonigral and striatopallidal neurons 29 . D1Rs have also been found on striatonigral terminals, and stimulation of these receptors can increase GABA release to the ventral tegmental area 30 . This would result in decreased striatal dopamine levels and could account for the observed increase in T34 phosphorylation in D2R neurons. The ability of D1R agonists to act on D2R neurons is not unprecedented, as a previous study showed that in vivo injection of a different D1R agonist resulted in cFos activation in both striatonigral and striatopallidal neurons 31 . These results highlight the complexity of dopamine signaling in vivo and suggest that both striatonigral and striatopallidal neurons can be affected by systemic injections of selective dopamine receptor agonists.
Conclusions
In addition to the drugs tested here, there are a variety of agents that have been shown to regulate DARPP-32 phosphorylation in striatal neurons 6 . For many of these drugs, it is not known whether they differentially affect signaling in striatonigral or striatopallidal neurons. The importance of selectively analyzing responses in these two neuronal populations is becoming increasingly clear, as recent studies have shown substantial differences between D1R-and D2R-expressing striatal neurons with regard to their synaptic properties and regulation of dendritic spine number [32] [33] [34] . We have expanded on these studies by developing a BAC transgenic mouse method that allows cell type-specific analysis of biochemical signaling events in these neurons. In principle, this methodology can be applied to study any type of post-translational modification on any protein in any cell type of interest. We expect that future studies using cell-type targeted approaches will be vital for a thorough understanding of cell signaling in the basal ganglia and other brain systems.
METHODS
Generation of tagged DARPP-32 BAC transgenic mice. All animal protocols were carried out in accordance with the US National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Rockefeller University Institutional Animal Care and Use Committee.
D1R-DARPP-32/Flag and D2R-DARPP-32/Myc BAC mice were generated according to the GENSAT BAC modification protocol 35 (detailed protocols for these procedures can be found at http://www.gensat.org). For the D1R-DARPP-32/Flag mouse, a 532-bp segment of the Drd1a promoter corresponding to the region immediately adjacent to the start codon was placed 5¢ to a mouse DARPP-32 cDNA containing a C-terminal Flag tag (DYKDDDDK) in a shuttle vector containing the IRES-Venus sequence. This modified shuttle vector was recombined into the BAC containing the full Drd1a promoter. BAC DNA from positive co-integrates was injected into pronuclei from FVB/N oocytes to generate transgenic mice.
For the D2R-DARPP-32/Myc mouse, a 484-bp segment of the Drd2 promoter corresponding to the region immediately adjacent to the start codon was placed 5¢ to mouse DARPP-32 cDNA containing a C-terminal Myc tag (SEQKLISEEDL). Venus cDNA was excised from the vector and replaced with ECFP cDNA (Clontech). This modified vector was recombined in to the Drd2 BAC and prepared as described above.
D1R/DARPP-32/Flag and D2R-DARPP-32/Myc mice were backcrossed more than ten generations to the C57Bl/6 background and bred to obtain double-transgenic mice expressing both Flag-and Myc-tagged DARPP-32. Male mice heterozygous for both Flag and Myc were used for all experiments.
In situ hybridization. We processed 12-mm sagittal sections of fresh frozen brain from wild-type and transgenic mice for in situ hybridization with a 35 Slabeled antisense riboprobe specific for full-length GFP using a protocol described previously 36 . Briefly, slides were fixed in 4% paraformaldehyde (wt/vol) and washed twice in 4Â sodium citrate/sodium chloride buffer (SSC, Ambion). Sections were acetylated for 10 min, dehydrated in a series of ethanols and incubated overnight at 55 1C in a humidity chamber with 2 Â 10 6 cpm of probe per slide mixed in hybridization buffer (20 mM Tris-HCl, 1 mM EDTA, 300 mM NaCl, 50% formamide (vol/vol), 10% dextran sulfate (wt/vol), 1Â Denhardt's solution, 250 mg ml -1 yeast tRNA, 100 mg ml -1 salmon sperm DNA, 0.1% SDS (vol/vol), 0.1% sodium thiosulfate (vol/vol)). Slides were washed four times in 4Â SSC and incubated with RNAse A for 15 min at 37 1C. Slides were then washed with a series of SSC buffers with decreasing concentration. Sections were dehydrated, dried and placed on Kodak MR film for 10 d.
To visualize GFP labeling at the cellular level, we dipped slides in Kodak NTB emulsion and left them in the dark for 6 weeks. Slides were developed and counterstained with cresyl violet. Pictures of labeled cells were taken on a Zeiss microscope using a 63Â water objective and AxioVision software.
FluoroGold retrograde labeling. We anesthetized 6-8-week-old D1R-DARPP-32/Flag and D2R-DARPP-32/Myc mice with sodium pentobarbital. The mice were placed in a stereotaxic apparatus (Kopf) and injected bilaterally with 1.0 ml of 0.8% FluoroGold (wt/vol, Fluorochrome, LLC) into the SNpr at a rate of 250 nl min -1 . Coordinates for injection into the SNpr were -2.9 anterior/ posterior, ±1.5 medial/lateral and -4.7 dorsal/ventral from bregma. Mice were perfused transcardially with 4% paraformaldehyde 5 d following the FluoroGold injection.
Immunohistochemistry. Adult mice were perfused transcardially with 4% paraformaldehyde. Brains were removed, post-fixed for 1 h and cryoprotected. We blocked 12-mm coronal sections for 1 h in 2% normal serum (vol/vol) and incubated them overnight at 4 1C with antibodies to FluoroGold (1:3,500, Chemicon), GFP (1:1,000, gift of M. Heiman, Rockefeller University), Flag (1:2,000, Sigma) or Myc (1:2,500 or 1:10,000, Novus). Slides were washed and incubated with the appropriate fluorescent secondary antibody (1:200) at room temperature (21-24 1C) for 1 h (Cy2, Cy3, FITC or rhodamine-red conjugated, all from Jackson ImmunoResearch). Fluorescent images were taken on a Zeiss confocal microscope using 40Â and 63Â oil objectives.
Flag-and Myc-tagged DARPP-32 immunoprecipitations. See Supplementary Methods online for the detailed protocol. Briefly, striata were sonicated in lysis buffer with protease and phosphatase inhibitors and incubated with EZView Red anti-Flag M2 affinity gel (Sigma) and Myc antibody-coupled (Novus) magnetic beads (Invitrogen) overnight at 4 1C. Flag and Myc beads were separated using a magnet (Invitrogen), washed, and bound proteins were eluted by boiling in sample buffer. The unbound homogenate was retained for the total striatum sample.
Immunoblotting. Flag immunoprecipitation, Myc immunoprecipitation and total striatum samples were loaded onto Tris-HCl gels, separated by electrophoresis and transferred to PVDF membranes. Membranes were blocked for 1 h in 5% milk (wt/vol) and incubated overnight at 4 1C with primary antibodies to phospho-T34 (1:5,000) 37 , phospho-T75 (1:7,500) 5 , Myc (1:750, Cell Signaling) or Flag (1:5,000, Sigma). Antibody binding was revealed by HRP-conjugated secondary antibodies (1:10,000) and the ECL detection method (PerkinElmer) with Kodak BioMax film. Membranes were stripped (Chemicon, Re-blot plus strong stripping buffer) and reprobed using a monoclonal antibody to DARPP-32 that is not phosphorylation-state specific 38 . Quantification of bands was performed by densitometry, using US National Institutes of Health Image software, version 1.52.
Striatal slice preparation. Acute striatal slices from 6-8-week-old D1R/D2R-DARPP-32 were prepared as described previously 29 (Supplementary Methods). Slices were treated for 5 or 10 min with vehicle, SKF 81297 or quinpirole (Sigma) as indicated. After the drug treatments, slices were transferred to Eppendorf tubes, flash frozen and subsequently processed for immunoprecipitation.
In vivo drug treatments. We used 6-8-week-old male D1R/D2R-DARPP-32 double-transgenic mice for all experiments. Mice were injected intraperitoneal with drug or vehicle and killed 15 min later using focused microwave irradiation. Brains were removed and striata were rapidly dissected and frozen at -80 1C until they were processed for immunoprecipitation. We used 5 mg per kg of body weight SKF 81297 (Tocris), 0.2 mg per kg quinpirole, 7.5 mg per kg caffeine, 25 mg per kg cocaine, 1 mg per kg haloperidol and 5 mg per kg clozapine (all from Sigma).
Statistics. Optical density of western blot bands from each treatment group were compared with the appropriate vehicle-treated group using unpaired, Student's t tests. Summary data on bar graphs display the mean and error bars represent s.e.m.
Note: Supplementary information is available on the Nature Neuroscience website.
